<DOC>
	<DOCNO>NCT02936037</DOCNO>
	<brief_summary>The purpose study demonstrate superiority MD1003 placebo disability patient suffer progressive multiple sclerosis especially gait impairment .</brief_summary>
	<brief_title>Effect MD1003 Progressive Multiple Sclerosis ( SPI2 )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Patient age 1865 year old Signed date write informed consent form accordance local regulation : freely give write informed consent participate study Diagnosis primary secondary progressive MS fulfilling revise McDonald criterion ( 2010 ) Lublin criterion ( 2014 ) Documented evidence clinical disability progression within 2 year prior inclusion , i.e . ) progression EDSS past two year least 1 point sustain least 6 month inclusion EDSS 3.5 5.5 least 0.5 point increase sustain least 6 month inclusion EDSS 6 6.5 b ) increase TW25 least 20 % last two year sustain least 6 month c ) welldocumented objective worsening validate Adjudication Committee EDSS inclusion 3.5 6.5 TW25 &lt; 40 second Kurtzke pyramidal functional subscore â‰¥2 define `` minimal disability : patient complain motorfatigability reduce performance strenuous motor task ( motor performance grade 1 ) and/or BMRC grade 4 one two muscle group '' Clinical evidence relapse 24 month prior inclusion Treatment product contain biotin single ingredient within six month prior inclusion ( multivitamin supplementation authorize biotin &lt; 1mg per day ) Concomitant treatment fampridine inclusion 30 day prior inclusion New immunosuppressive/immunomodulatory drug initiate less 90 day prior inclusion Treatment botulinium toxin ( except cosmetic purpose ) initiate within 6 month prior inclusion Inpatient rehabilitation program within 3 month prior inclusion Pregnancy , breastfeed woman childbearing potential without acceptable form contraception Men unwilling use acceptable form contraception Any general chronic handicapping/incapacitating disease MS Any serious disease necessitate biological followup biological test use biotinylated antibody substrates Past history rhabdomyolysis/metabolic myopathy Known fatty acid beta oxidation defect Known hypersensitivity intolerance biotin , analogues excipients , patient rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption Patients hypersensitivity contraindication Gadolinium Patients uncontrolled hepatic disorder , renal cardiovascular disease , cancer Laboratory test normal range consider investigator clinically significant regard study continuation Patients history presence alcohol abuse drug addiction Untreated uncontrolled psychiatric disorder , especially suicidal risk assess ColumbiaSuicide Severity Rating Scale ( CSSRS ) Participation another research study involve investigational product ( IP ) 90 day prior inclusion , plan use study duration Patients likely noncompliant study procedure longterm followup seem difficult achieve Relapse occur inclusion randomization visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>progressive multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>EDSS</keyword>
	<keyword>TW25</keyword>
	<keyword>multiple sclerosis</keyword>
</DOC>